CLINICAL-MICROBIOMICS AS

Their core work

Clinical-Microbiomics is a Danish private company specializing in microbiome analysis and interpretation for research and clinical applications. They provide advanced multi-omics services — metagenomics, metatranscriptomics, and metabolomics — to help research consortia understand the role of gut microbiota in human health conditions. Their H2020 involvement spans gut microbiome engineering for obesity treatment, gut-brain-axis research in aging, and data-driven approaches to combating bacterial infections. As a commercial microbiomics service provider, they bring industrial-grade bioinformatics and big data integration capabilities to academic-led research networks.

What they specialise in

How they've shifted over time

Clinical-Microbiomics entered H2020 in 2018 with a tight focus on gut microbiome characterization and metabolic disease (obesity, cytokines, metatranscriptomics in BestTreat). By 2020-2021, their scope broadened significantly — into neuroscience applications via the gut-brain-axis (SmartAge) and into infection microbiology with machine learning and even graphene-based sensor technologies (PEST-BIN). This trajectory shows a company expanding from pure microbiome analytics into interdisciplinary health applications where microbial data intersects with AI, materials science, and clinical aging research.

Moving from core microbiome sequencing services toward data-intensive, AI-augmented microbial analysis across diverse health domains — positioning themselves as a versatile microbiomics partner beyond metabolic disease.

How they like to work

Clinical-Microbiomics operates exclusively as a participant, never as coordinator — consistent with their role as a specialized service company embedded in larger research networks. With 33 unique partners across 14 countries from just 3 projects, they engage in large MSCA training networks (averaging 11+ partners per consortium). This pattern suggests they are a sought-after commercial partner that academic consortia bring in for specialized microbiome analytics capacity.

Despite only three projects, Clinical-Microbiomics has built a remarkably broad network of 33 partners across 14 countries, reflecting the large MSCA-ITN consortia they participate in. Their reach is pan-European with no visible geographic concentration.

What sets them apart

As a private SME focused entirely on clinical microbiomics, they occupy a niche that most academic labs cannot — translating complex multi-omics microbiome data into actionable insights at commercial quality standards. Their participation in MSCA training networks suggests they also serve as an industry training ground for early-stage researchers, bridging the gap between academic microbiome science and commercial application. For consortium builders, they offer a rare combination: deep microbiome bioinformatics expertise with the agility and IP flexibility of a Danish SME.

Highlights from their portfolio

• BestTreat
  Their first H2020 project and most aligned with their core business — building a gut microbiome engineering toolbox for therapeutic treatments, directly linking microbiomics to clinical intervention.
• PEST-BIN
  Represents the broadest expansion of their capabilities, combining infection microbiology with machine learning and graphene-based technologies — an unusual interdisciplinary stretch for a microbiomics company.
• SmartAge
  Connects microbiome expertise to neuroscience and aging research via the gut-brain-axis, opening a high-impact application domain with growing clinical and commercial relevance.